Verification report on the deposit and actual use of raised funds of Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd. in 2021
Beijing Institute of Certified Public Accountants
Business report unified coding reporting system
Unified business reporting code: 110 Andon Health Co.Ltd(002432) 0229 Tunghsu Azure Renewable Energy Co.Ltd(000040) 70
Name of previous report of Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd.:
Special audit on the use of raised funds
Report No.: Ernst & Young Huaming (2022) ZZ No. 60468439b02
Name of audited (inspected) unit: Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd
Name of accounting firm: Ernst & Young Huaming Certified Public Accountants (special general partnership)
Business type: special audit
Report date: March 28, 2022
Filing date: March 28, 2022
Bao Xiaogang (110 Andon Health Co.Ltd(002432) 550),
Signed by:
Xia Chanyu (31 Shenzhen Zhenye(Group)Co.Ltd(000006) 619)
(information can be queried by scanning QR code or logging into the official website of Beijing injection Association)
Note: this filing information only proves that the report has been filed with the Beijing Institute of certified public accountants, and does not mean that the Beijing Institute of Certified Public Accountants makes any form of guarantee for the content of the report in any sense.
Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd
catalogue
Page 1. Verification report on the deposit and actual use of raised funds 1 – 2 2 Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd
Special report on the deposit and actual use of raised funds in 2021 3 – 9
Special report on the deposit and actual use of raised funds
Year 2021
1、 Basic information of raised funds (I) actual amount of raised funds and arrival time
Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd. (hereinafter referred to as “the company” or “the company”) was examined and approved by the stock listing committee of science and Innovation Board of Shanghai Stock Exchange on May 11, 2020, and approved by the reply on Approving the registration of initial public offering of Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd. (zjxk [2020] No. 1217) of China Securities Regulatory Commission on June 23, 2020, 61621142 ordinary shares (A shares) in RMB were issued in the initial public offering, with an issue price of 28.18 yuan per share and a total raised capital of 173648378156 yuan. The sponsor (lead underwriter) of this offering, Huatai United Securities Co., Ltd., will deduct the underwriting fee (including value-added tax) of 7822859436 yuan belonging to Huatai United Securities Co., Ltd. and remit the total capital of 165825518720 yuan to the following account opened by the company: Industrial And Commercial Bank Of China Limited(601398) Shanghai Zhangjiang sub branch, with an account number of 1001194909061273331. After the above amount is paid to the joint lead underwriter Citic Securities Company Limited(600030) underwriting fee and other issuance expenses (including value-added tax), the remaining funds are the net funds raised by the company, totaling 163442818764 yuan. The above raised funds have been verified by Ernst & Young Huaming Certified Public Accountants (special general partnership), and the capital verification report (Ernst & Young Huaming (2020) Yan Zi No. 60468439b01) was issued on July 17, 2020. (II) use amount and balance of raised amount during the reporting period
As of December 31, 2021, the use and balance of the raised funds of the company are as follows:
Project amount (RMB)
The total amount of raised funds is 173648378156
Less: lead underwriter’s underwriting fee 7822859436
The total amount of raised funds actually received is 165825518720
Less: 1228888544 of the amount paid in advance by replacing the issue expenses with the raised funds
Less: the amount of issuance expenses paid in 2020 is 1153811412
Net proceeds 163442818764
Less: 13230689212 amount of self raised funds invested in advance replaced by raised funds
Less: 36453081575 yuan invested in the project of raising funds
Including: the amount invested in the project of raising funds in 2021 is 17646865043
Plus: interest income 2615206811
The balance of raised funds is 11637454788
Less: structural deposit balance 30000000000
The balance of the special account for raised funds is 86374254788
Special report on the deposit and actual use of raised funds (Continued)
Year 2021
2、 Management of raised funds (I) management of raised funds
In order to standardize the management and use of raised funds, improve the efficiency and efficiency of fund use and protect the interests of investors, the company
According to the company law, the securities law and the guidelines for the supervision of listed companies No. 2 – management and use of raised funds of listed companies
Regulatory requirements for the listing of shares on the science and Innovation Board of Shanghai Stock Exchange (revised in December 2020) and Shanghai Securities
The measures for the administration of funds raised by listed companies of the exchange (revised in 2013) and other relevant laws, regulations and normative documents,
Combined with the actual situation of the company, the company has formulated the management system of raised funds of Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd
(hereinafter referred to as “raised funds management system”).
According to the fund raising management system of the company
The special account storage system shall establish a special account for raising funds in the bank. The company together with the sponsor Huatai United Securities Co., Ltd
The company signed contracts with China Merchants Bank Co.Ltd(600036) Shanghai Zhangjiang sub branch and China Citic Bank Corporation Limited(601998) Shanghai branch respectively
The tripartite supervision agreement on the storage of raised funds specifies the rights and obligations of all parties.
The company and its subsidiary Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Suzhou) Co., Ltd. together with the sponsor Huatai United Securities Co., Ltd
The company and Industrial And Commercial Bank Of China Limited(601398) Shanghai Zhangjiang science and technology sub branch signed the special account for raised funds storage agreement
Management agreement; The company and its subsidiary Shanghai Shengguo Pharmaceutical Development Co., Ltd. together with the sponsor Huatai United Securities Co., Ltd
Ren company and China Citic Bank Corporation Limited(601998) Shanghai Branch signed the quadripartite supervision agreement on the storage of special account for raised funds, which states:
The rights and obligations of all parties have been clarified.
There is no significant difference between the above regulatory agreement and the model regulatory agreement of Shanghai Stock Exchange. The company is using the raised capital
The fund has been strictly complied with and performed in order to facilitate the management and use of the raised funds and supervise their use to ensure
Earmarked. (II) special account storage of raised funds
As of December 31, 2021, the special accounts for raised funds of the company and its subsidiaries are as follows:
Balance of special account for raised funds in the bank account of the company’s deposit bank (RMB)
Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Suzhou) Co., Ltd. Industrial And Commercial Bank Of China Limited(601398) Shanghai Pudong soft 100107242907 Shantui Construction Machinery Co.Ltd(000680) 62139121214 Jianyuan sub branch
Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd. China Merchants Bank Co.Ltd(600036) Shanghai Zhangjiang sub branch 12190793201042013729454844
Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd. China Merchants Bank Co.Ltd(600036) Shanghai Zhangjiang sub branch 1219079320102218170228247
Shanghai Shengguo Pharmaceutical Development Co., Ltd. China Citic Bank Corporation Limited(601998) Shanghai Dahua Jinxiu sub branch 81102010141012127131864917892
Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd. China Merchants Bank Co.Ltd(600036) Shanghai Zhangjiang sub branch 1219079320109231840.09
Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd. China Citic Bank Corporation Limited(601998) Shanghai Dahua Jinxiu sub branch 8110201014401212707470348582
Total 86374254788
Special report on the deposit and actual use of raised funds (Continued)
Year 2021
3、 Actual use of raised funds in 2021 (I) use of funds for investment projects with raised funds
According to the application plan of the raised funds disclosed in the prospectus of the company’s initial public offering of RMB common shares (A shares), after deducting the issuance expenses, all the funds raised from the stock issuance will be used for the raised capital investment projects and supplementary working capital related to the main business of Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd.
As of December 31, 2021, the actual use of the raised funds is shown in “Annex 1: comparison table of the use of the raised funds”. (II) advance investment and replacement of investment projects with raised funds
On November 5, 2020, the company held the 18th meeting of the third board of directors to consider and approve the proposal on replacing self raised funds invested in investment projects with raised funds in advance. The company used raised funds to replace self raised funds invested in investment projects with raised funds in advance, with a total amount of 13230689212 yuan, The total amount of issuing expenses paid in advance with self raised funds is 1228888544 yuan, and the total amount of self raised funds is 14459577756 yuan. The above situation of self raised funds pre invested in projects invested with raised funds has been verified by Ernst & Young Huaming Certified Public Accountants (special general partnership) and issued the special verification report on the situation of Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd. pre invested projects invested with raised funds with self raised funds (Ernst & Young Huaming (2020) ZZ No. 60468439b06). The independent directors of the company have expressed explicit consent to the above matters, and the sponsor Huatai United Securities Co., Ltd. has issued explicit consent verification opinions on the above matters. (III) temporarily replenish liquidity with idle raised funds
